Immune Rejection Articles & Analysis
8 news found
“We currently manage high-level BK viremia by reducing immunosuppressive therapy, which can help a patient’s immune system clear the virus, but this approach raises the risk that the immune system will attack and reject the graft. ...
ByKalaris
VX-880 is delivered by an infusion into the hepatic portal vein and requires maintenance immunosuppressive therapy to protect the islet cells from immune rejection. About the Phase 1/2 Clinical Trial The clinical trial is a Phase 1/2, multi-center, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. ...
VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. About the Phase 1/2 Clinical Trial The clinical trial is a Phase 1/2, multi-center, single-arm, open-label study in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. ...
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- Data support an expected Investigational New Drug (IND) application submission in 2022 for CB-011, Caribou’s second allogeneic cell therapy product candidate -- Caribou ...
(Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living ...
With typical organ transplants, immuno-suppressive drugs are required to prevent the patient's immune system from rejecting the donated organ. Because the Biostage Esophageal Implant is made using the patient's own cells, Biostage does not expect rejection of the implant. ...
"It seems that mitochondria are immune privileged — we have not seen that they elicit an immune response or any rejection or deterioration of cell functions by transplanting foreign mitochondria," stated Schueller. ...
However, there is a much greater need for research into implants that are intended to replace elastic tissue, because the demands on the materials are high: they must retain their mechanical properties for many years, be 100 percent resistant and biocompatible, and must not cause rejection reactions by the immune system. The latter is particularly important for ...